I L Silva1, M Iskandarani2, A Hotouras3,4, J Murphy5, C Bhan1, B Adada6, S D Wexner7. 1. Department of Surgery, Whittington Hospital, London, UK. 2. Department of Surgery, The Royal London Hospital, London, UK. 3. Department of Surgery, The Royal London Hospital, London, UK. alex007@doctors.org.uk. 4. National Centre for Bowel Research and Surgical Innovation, Barts and the London, School of Medicine and Dentistry, 2 Newark Street, London, E12AT, UK. alex007@doctors.org.uk. 5. Department of Surgery, St Mary's Hospital, Imperial College London, London, UK. 6. Department of Neurological Surgery, Cleveland Clinic Florida, Fort Lauderdale, FL, USA. 7. Digestive Disease Center, Cleveland Clinic Florida, Fort Lauderdale, FL, USA.
Abstract
BACKGROUND: Colorectal cancer (CRC) rarely metastasizes to the brain. The incidence of cerebral metastases (CM) is estimated between 1 and 3%. Given the improved survival from advanced CRC as a result of surgical and oncological advances, it is anticipated that the incidence of patients with CM from CRC will rise over the next few years. The aim of this article was to systematically review the treatment options and outcome of patients with CM from CRC. METHODS: PubMed and Medline databases were examined using the search words or MESH headings "colorectal" "cancer/carcinoma/adenocarcinoma", "cerebral"/"brain" and "metastases/metastasis". RESULTS: CM from CRC are diagnosed on average 28.3 months after the primary tumour. The median survival time following diagnosis is 5.3 months. Surgery (with or without associated radiotherapy), stereotactic radiosurgery, whole brain radiotherapy and best supportive care result in median survival of 10.3, 6.4, 4.4 and 1.8 months, respectively. On average, the 1-year overall survival rate for patients with CM from CRC regardless of the treatment modality is estimated to be around 24%. CONCLUSIONS: The prognosis of patients with CM from CRC is dismal. Surgery may increase survival, but the additional benefit of perioperative radiotherapy cannot be ascertained due to paucity of data. Further studies are required to identify the role of the different oncological and surgical therapies and identify those patients likely to benefit most. Identification of patients who are at higher risk of developing brain metastases may be another important area for future research.
BACKGROUND:Colorectal cancer (CRC) rarely metastasizes to the brain. The incidence of cerebral metastases (CM) is estimated between 1 and 3%. Given the improved survival from advanced CRC as a result of surgical and oncological advances, it is anticipated that the incidence of patients with CM from CRC will rise over the next few years. The aim of this article was to systematically review the treatment options and outcome of patients with CM from CRC. METHODS: PubMed and Medline databases were examined using the search words or MESH headings "colorectal" "cancer/carcinoma/adenocarcinoma", "cerebral"/"brain" and "metastases/metastasis". RESULTS: CM from CRC are diagnosed on average 28.3 months after the primary tumour. The median survival time following diagnosis is 5.3 months. Surgery (with or without associated radiotherapy), stereotactic radiosurgery, whole brain radiotherapy and best supportive care result in median survival of 10.3, 6.4, 4.4 and 1.8 months, respectively. On average, the 1-year overall survival rate for patients with CM from CRC regardless of the treatment modality is estimated to be around 24%. CONCLUSIONS: The prognosis of patients with CM from CRC is dismal. Surgery may increase survival, but the additional benefit of perioperative radiotherapy cannot be ascertained due to paucity of data. Further studies are required to identify the role of the different oncological and surgical therapies and identify those patients likely to benefit most. Identification of patients who are at higher risk of developing brain metastases may be another important area for future research.
Authors: Ji Yeon Baek; Myoung Hee Kang; Yong Sang Hong; Tae Won Kim; Dae Yong Kim; Jae Hwan Oh; Seung Hoon Lee; Jin Hong Park; Jong Hoon Kim; Sun Young Kim Journal: J Neurooncol Date: 2011-02-19 Impact factor: 4.130
Authors: Giuseppe Aprile; Elisa Zanon; Francesco Tuniz; Emiliana Iaiza; Federica De Pauli; Nicoletta Pella; Stefano Pizzolitto; Alberto Buffoli; Andrea Piga; Miran Skrap; Gianpiero Fasola Journal: J Cancer Res Clin Oncol Date: 2008-09-09 Impact factor: 4.553
Authors: Luis Del Carpio Huerta; Anna Cristina Virgili Manrique; Justyna Szafranska; Marta Martin-Richard; David Paez Lopez-Bravo; Ana Sebio Garcia; Iñigo Espinosa Mariscal; Paula Gomila Pons; Marta Andres Granyo; Andres Barba Joaquin; Agusti Barnadas Molins; Maria Tobeña Puyal Journal: Int J Colorectal Dis Date: 2018-06-25 Impact factor: 2.571
Authors: Caroline Sander; Clara Frydrychowicz; Gordian Prasse; Sabine Taubenheim; Felix Arlt; Jürgen Meixensberger; Michael Karl Fehrenbach Journal: BMC Cancer Date: 2022-03-28 Impact factor: 4.430